Objective: Acute myocardial infarction (AMI) carries increased risk of mortality and excess costs. Disease Management Programs (DMPs) providing guideline-recommended care for chronic diseases seem an intuitively appealing way to enhance health outcomes for patients with chronic conditions such as AMI. The aim of the study is to compare adherence to guideline-recommended medication, health care expenditures and survival of patients enrolled and not enrolled in the German DMP for coronary artery disease (CAD) after an AMI from the perspective of a third-party payer over a follow-up period of 3 years. Methods: The study is based on routinely collected data from a regional statutory health insurance fund (n = 15,360). A propensity score ma...
BackgroundThe relationship between guideline adherence and outcomes in patients with acute myocardia...
The aim of this study was to investigate the cost-effectiveness of statin use by newly hospitalised ...
AIMS: To investigate the 'real world' effectiveness of robust statin therapy, focusing on the effect...
BACKGROUND: Cardiac disease management programmes (CHD-DMPs) and secondary cardiovascular prevention...
PURPOSE Secondary medication prevention after acute myocardial infarction (MI) is strongly recommen...
International audienceMyocardial infarction is a major cause of morbidity and mortality. Guidelines ...
Myocardial infarction is a major cause of morbidity and mortality. Guidelines have been published to...
Background Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), be...
OBJECTIVE: To evaluate healthcare and outcomes of disease management programmes (DMPs) for patients ...
BACKGROUND:The 20% observed mortality within 5 years among survivors of myocardial infarction may be...
BACKGROUND: After myocardial infarction, guidelines recommend pharmaceutical treatment with a combin...
To determine long-term adherence to evidence-based secondary preventive combination pharmacotherapy ...
BackgroundNonadherence to prescribed evidence-based medications after acute myocardial infarction (M...
Aims: To investigate the 'real world' effectiveness of robust statin therapy, focusing on the effect...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
BackgroundThe relationship between guideline adherence and outcomes in patients with acute myocardia...
The aim of this study was to investigate the cost-effectiveness of statin use by newly hospitalised ...
AIMS: To investigate the 'real world' effectiveness of robust statin therapy, focusing on the effect...
BACKGROUND: Cardiac disease management programmes (CHD-DMPs) and secondary cardiovascular prevention...
PURPOSE Secondary medication prevention after acute myocardial infarction (MI) is strongly recommen...
International audienceMyocardial infarction is a major cause of morbidity and mortality. Guidelines ...
Myocardial infarction is a major cause of morbidity and mortality. Guidelines have been published to...
Background Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), be...
OBJECTIVE: To evaluate healthcare and outcomes of disease management programmes (DMPs) for patients ...
BACKGROUND:The 20% observed mortality within 5 years among survivors of myocardial infarction may be...
BACKGROUND: After myocardial infarction, guidelines recommend pharmaceutical treatment with a combin...
To determine long-term adherence to evidence-based secondary preventive combination pharmacotherapy ...
BackgroundNonadherence to prescribed evidence-based medications after acute myocardial infarction (M...
Aims: To investigate the 'real world' effectiveness of robust statin therapy, focusing on the effect...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
BackgroundThe relationship between guideline adherence and outcomes in patients with acute myocardia...
The aim of this study was to investigate the cost-effectiveness of statin use by newly hospitalised ...
AIMS: To investigate the 'real world' effectiveness of robust statin therapy, focusing on the effect...